The words Psilocybin. Ketamine, and other psychoactives come up in my office more often these days than the word medication. Couples ask about it. Individuals ask about it. People are historically skeptical of SSRI treatments, but seemingly very open to the possibilities that these new, yet old, drugs will be the miracles we’ve all hoped for in the fight against anxieties and depressions.
The interest makes sense. Depression is heavy, the usual treatments help some people and leave others where they started, and the headlines promise something different: one or two powerful experiences instead of a daily pill for years. In 2026 that promise moved closer to the real world. Two large psilocybin trials finished, an LSD-based drug reported three positive late-stage trials, and the first FDA decision on psilocybin could arrive in 2027.
This is my attempt to separate the signal from the noise. I’m a psychotherapist and relationships expert, not a prescriber, and nothing here is medical advice. What I can offer is a careful reading of what the research shows, what it doesn’t show yet, and why I think the relationship around a person may carry as much weight as the molecule they take.
Psilocybin is the most studied of the group. In two large trials of people with treatment-resistant depression, meaning depression that hadn’t lifted after several medications, a single 25 mg dose beat placebo by 3.6 points on a standard 60-point depression scale, and two doses beat a tiny control dose by 3.8 points (trial results). These participants were not mildly down. Their current episodes had lasted more than three years on average (Compass Pathways).
That’s real progress, and it’s also modest. About a quarter of people in the first trial, and roughly four in ten in the second, reached a meaningful improvement, defined as a drop of at least 25 percent in symptoms (Compass, February 2026). Read the other way, most people did not. The company is finishing its FDA application this quarter and hopes to launch in the first half of 2027 if it’s approved (STAT).
LSD was the surprise of the year. A pharmaceutical form called DT120 produced the largest numbers in the field. In a trial of 149 adults with major depression, one 100 microgram dose beat placebo by 8.1 points, and 24 percent reached remission compared with 3 percent on placebo (HCPLive). Two trials in generalized anxiety were also positive (Panorama results). Even so, about three in four people who took the drug did not reach remission. These late-stage results are still company announcements rather than peer-reviewed papers, and an FDA filing is expected in the first half of 2027 (Panabee).
Every one of these trials shares a weakness. People almost always know whether they got the real drug. In psychedelic studies, participants guess correctly about 90 to 95 percent of the time, compared with about 60 percent in antidepressant trials (Balázs Szigeti). Once you know you got the real thing, hope does some of the work, and the study can’t tell how much.
In March 2026, a team writing in JAMA Psychiatry tried a fairer comparison. Instead of measuring psychedelic therapy against placebo, they compared it with antidepressant studies where patients also knew what they were taking. Across 24 studies, the two came out nearly even. That doesn’t mean psychedelics fail. Both groups improved a great deal. It means the advantage over standard care may be smaller than the headlines suggest, and expectation may explain more of it than anyone would like.
Ask yourself what you’d expect to feel after weeks of preparation, a full day of undivided attention, and a story everyone around you believes in. Some of the healing in that picture is the drug. Some of it is being taken seriously, maybe for the first time. Nobody knows the split yet.
Ketamine is the one option already approved, as the nasal spray Spravato for treatment-resistant depression. It can work within a day, but the effect often fades and needs repeating. When researchers at Stanford gave IV ketamine or saline to depressed patients who were under anesthesia for surgery, so nobody could tell which they got, ketamine did no better than placebo (Nature Mental Health). Both groups improved. The daily low-dose ketamine sold through telehealth companies has almost no controlled evidence behind it. But they will likely saturate the market soon.
DMT and its cousin 5-MeO-DMT are the short-acting branch, with experiences that last minutes rather than hours. An inhaled 5-MeO-DMT product called GH001 lowered depression scores by about 15 points more than placebo after one week in 81 people with treatment-resistant depression, and most were ready to go home an hour after treatment (BioSpace). An IV DMT trial in 34 people showed a 7.4-point advantage at two weeks (Panabee). Both are small and early, and the company behind the IV DMT trial isn’t developing that version further (Psychiatric Times).
MDMA was tested for PTSD, not depression. The FDA declined to approve it in 2024 and asked for another trial, after concerns about weak data and allegations of misconduct during sessions (Washington Times). Ibogaine has striking results from a Stanford study of special operations veterans, but that study had no control group, and the drug can cause fatal heart rhythm problems (Ynet). Texas has committed $50 million to proper trials (Detox.com). Mescaline has no clinical trials for depression, only surveys of people who used it on their own (OPEN Foundation).
Ranked by evidence today, psilocybin and LSD lead. Ketamine is the best known but short-lived. The short-acting DMT drugs are promising but early. MDMA, ibogaine and mescaline aren’t ready to be part of anyone’s plan for depression.
None of this is risk-free. In the large 2022 psilocybin trial published in the New England Journal of Medicine, side effects like headache, nausea and dizziness were common, and some participants in every group had suicidal thoughts or self-injury, with more in the higher-dose groups (Healio). Outside of clinics the picture is rougher. In a Johns Hopkins survey of nearly 2,000 people, 39 percent said their worst psilocybin experience ranked among the five most difficult of their lives (Carbonaro et al.). Among 608 people who struggled after a psychedelic experience, about a third had problems that lasted more than a year (Evans et al.).
Trials also screen many people out, typically anyone with a personal or family history of psychosis or bipolar disorder, serious heart problems, or an active substance use disorder. When you hear someone’s success story, remember that the person telling it was probably screened in. Also, always remember that anecdotal evidence is not how we know things, it’s how we get curious about things.
One practical point surprises people. Common antidepressants like SSRIs and SNRIs can blunt psilocybin’s effects, and survey data from Johns Hopkins suggest that blunting can last up to three months after stopping (PsyPost). Trials usually taper people off first, under medical supervision. Please don’t stop an antidepressant on your own to prepare for a psychedelic experience without talking it through with your doctor and a good titration plan.
Depression never happens to just one person in a couple. It changes the conversations, the sex, who carries what, and the way each partner reads the other’s silence. So I watch the small body of research on psychedelics and relationships closely.
The best-known study gave MDMA to six couples, one partner in each with PTSD, inside a structured couples therapy. PTSD symptoms, depression and relationship satisfaction all improved, and there were no serious adverse events (Monson et al., 2020). Six couples is a pilot, with no control group. A 2025 doctoral study of couples who took psilocybin together described partners becoming more accessible, responsive and engaged with each other, and proposed the idea of a relational set and setting (City St George’s, University of London). That’s a close look at a few couples, not a trial.
Internal Family Systems, the parts-based model I use with couples, keeps showing up in this conversation too. Its founder, Richard Schwartz, has argued that psychedelics quiet the protective parts of us and open faster access to the wounded ones (The Psychedelic Podcast). I suspect that to be true as well. I find that idea compelling, and it fits what people describe. But there are still very few controlled studies of IFS paired with psychedelics (Unlimited Sciences). For now it’s a promising map, not tested territory.
What I’m convinced of is simpler. A powerful experience can open a person up, and what happens next depends on the container around it: preparation that clarifies what you hope for, a partner who knows how to listen when you come back changed, and someone to help make sense of what surfaced. The drug companies are moving toward minimal, standardized support, partly because the FDA wants consistency, and even researchers running these trials are asking how much good psychotherapy adds beyond basic monitoring (HCPLive). That question is open. I suspect the answer is a lot, and I hold it as a hypothesis.
Psilocybin is still a Schedule I drug under federal law. North Carolina has no legal access program, and the bills in the General Assembly would fund research rather than open clinics (Blossom). The legal routes today are clinical trials, listed on ClinicalTrials.gov, and the state programs in Oregon and Colorado, where licensed centers offer supervised sessions that typically cost $500 to $2,500 and aren’t covered by insurance (Healing Maps). New Mexico is building a medical program that runs through licensed health care providers (Mugglehead).
If psilocybin is approved, expect it to arrive under tight FDA rules similar to Spravato’s: certified clinics, trained staff and hours of monitoring (Vicente LLP). Expect it to be expensive and hard to get at first.
Before you or your partner try anything, a few questions do a lot of work. Is this a trial, a licensed program, or an underground guide? Who screened you, and for what? Who will be in the room, and what is their training? What’s the plan for the days and weeks afterward? And what does your prescriber say about the medications you take now? If anyone sells you a psychedelic as a cure, they’re outrunning the data. I think thinking of it as a promising tool is the better ideation.
The hope is real, and it’s narrower than the hype and sturdier than the skeptics allow. Within a few years, psilocybin and probably LSD are likely to become options for some people whom standard treatment hasn’t helped. For a few of them, one or two sessions may shift something that years of daily medication didn’t. For most, it will be one tool among several, and it won’t replace the slower work of changing how we live and love.
I don’t provide psychedelics, and in North Carolina no therapist legally can. What I do is help couples prepare for big decisions and make sense of big experiences: getting clear on what each partner hopes for and fears, mapping the patterns depression has pressed into the relationship, and helping you integrate whatever you bring home, whether that’s from ketamine treatment, a future approved psilocybin treatment, or an experience you’re still trying to understand. A molecule might open a door. The two of you still have to walk through it together.
If you’re weighing one of these treatments, or you’re living alongside a partner who is, you can start with a session or take the Inner Compass Assessment to see the patterns you’re working with before anyone takes anything.
This article is for education, not medical advice. Talk with a qualified prescriber before starting, stopping or combining any medication.
